0001209191-17-059629.txt : 20171107
0001209191-17-059629.hdr.sgml : 20171107
20171107170820
ACCESSION NUMBER: 0001209191-17-059629
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171107
FILED AS OF DATE: 20171107
DATE AS OF CHANGE: 20171107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jenkins Annalisa
CENTRAL INDEX KEY: 0001639481
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37601
FILM NUMBER: 171184308
MAIL ADDRESS:
STREET 1: C/O ARDELYX, INC.
STREET 2: 34715 ARDENWOOD BLVD, SUITE 100
CITY: FREMONT
STATE: CA
ZIP: 94555
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dimension Therapeutics, Inc.
CENTRAL INDEX KEY: 0001592288
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463942159
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-401-0011
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-07
1
0001592288
Dimension Therapeutics, Inc.
DMTX
0001639481
Jenkins Annalisa
C/O DIMENSION THERAPEUTICS, INC.
840 MEMORIAL DRIVE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Stock Option (Right to Buy)
0.56
2017-11-07
4
D
0
481696
D
2024-09-24
Common Stock
481696
0
D
Stock Option (Right to Buy)
3.57
2017-11-07
4
D
0
74375
D
2025-04-28
Common Stock
74375
0
D
Stock Option (Right to Buy)
4.09
2017-11-07
4
D
0
342113
D
2025-06-02
Common Stock
342113
0
D
Stock Option (Right to Buy)
7.14
2017-11-07
4
D
0
160000
D
2026-01-31
Common Stock
160000
0
D
Stock Option (Right to Buy)
1.90
2017-11-07
4
D
0
192000
D
2027-01-31
Common Stock
192000
0
D
Stock Option (Right to Buy)
1.35
2017-11-07
4
D
0
150000
D
2027-07-02
Common Stock
150000
0
D
This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This stock option, which vests over four years beginning June 3, 2015, at a rate of 6.25% on September 23, 2015, and in 45 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This stock option, which vests in 48 equal monthly installments beginning January 28, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
This option, which vests on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
/s/ Mary Thistle, as Attorney-in-Fact for Annalisa Jenkins
2017-11-07